HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer Meeting Abstract


Authors: Borad, M. J.; Shroff, R. T.; Abou-Alfa, G. K.; Hecht, J. R.; Bullock, A. J.; Ritch, P. S.; Chondros, D.; Muhsin, M.; Oh, D. Y.
Abstract Title: HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer
Meeting Title: 2018 Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 4 Suppl.
Meeting Dates: 2018 Jan 18-20
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-01
Language: English
ACCESSION: WOS:000436174100523
PROVIDER: wos
DOI: 10.1200/JCO.2018.36.4_suppl.TPS543
Notes: Meeting Abstract: TPS543 -- Source: Wos
Altmetric Score
MSK Authors
  1. Ghassan Abou-Alfa
    225 Abou-Alfa